Femoral pseudoaneurysms arise in up to 2% of patients after femoral cannulation for cardiac catheterisation. We used autologous thrombin for percutaneous obliteration of pseudoaneurysms occurring after catheterisation. We prepared autologous thrombin isolates from blood of ten patients with femoral pseudoaneurysms, and injected this solution into the pseudoaneurysms with duplex imaging guidance. We then assayed thrombin activity. All pseudoaneurysms were successfully thrombosed without substantial complications, although three patients needed a repeat procedure within 24 h. We have shown that autologous thrombin-induced thrombosis of pseudoaneurysms is reliable, simple, safe, and cheaper than commercial bovine or human thrombin, and avoids risks of anaphylaxis and contamination with prions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(02)07991-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemostatic conditions following autologous transfusion of fresh vs stored platelets in experimental endotoxemia: an open-label randomized controlled trial with healthy volunteers.
Res Pract Thromb Haemost
November 2024
Department of Intensive Care Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Article Synopsis
- The study aimed to investigate how fresh and stored platelet concentrates (PCs) behave during inflammation, specifically in a controlled human model of endotoxemia induced by lipopolysaccharide (LPS).
- Researchers found that LPS increased markers related to coagulation and clotting, leading to a generally lower clotting ability in subjects compared to controls, while platelet transfusions improved clotting time and strength in those with endotoxemia.
- Despite these improvements in coagulation, there were no significant differences noted between the effects of fresh versus stored platelets on coagulation parameters like thrombin-antithrombin complex (TATc) or extracellular vesicles (EVs).
Harmony in Healing: Investigating Platelet-Rich Plasma Activation during Acetylsalicylic Acid Treatment.
Int J Mol Sci
October 2024
Department of Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Łukasiewicza 1, 85-821 Bydgoszcz, Poland.
Platelet-rich plasma (PRP) therapy holds promise for treating various clinical conditions. The activation process is crucial in releasing growth factors and cytokines from platelets, enhancing the therapeutic properties of PRP. Standard activation methods involve autologous thrombin or collagen, with variations in efficacy and growth factor release.
View Article and Find Full Text PDFEffect of aspirin on platelet-rich plasma of diabetes mellitus with lower extremity atherosclerosis.
Future Sci OA
December 2024
Department of Endocrinology, General Hospital of Central Theater Command, Wuhan, Hubei Province, 430070, China.
Article Synopsis
- Platelet-rich plasma (PRP) is being studied as a potential treatment for diabetic foot ulcers (DFUs), but the impact of aspirin on its growth factor content is still unclear.
- The study compared PRP from diabetic patients taking aspirin with those not taking it, and found that both had lower growth factor levels than a control group of healthy volunteers.
- Results showed that while aspirin use does not hinder PRP therapy, PRP from healthy individuals is more effective for enhancing the healing of DFUs compared to that from diabetic patients.
Preclinical evaluation of a novel endovascular thrombectomy device in a modified swine model for iliac vein thrombosis.
Heliyon
October 2024
Department of Vascular Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Article Synopsis
- This study aimed to test the safety and effectiveness of a new thrombectomy device (Zylox) for treating iliac vein thrombosis in a specially designed pig model.
- The modified model successfully created bilateral iliac vein thrombosis in 12 pigs, allowing for direct comparison of the Zylox device to an existing device (AcoStream).
- Results showed that although the Zylox group had longer thrombus lengths, it resulted in significantly less blood loss and maintained vein patency without complications, highlighting its potential advantages for future human clinical trials.
Development of in situ forming autologous fibrin scaffold incorporating synthetic teriparatide peptide for bone tissue engineering.
Int J Artif Organs
September 2024
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Introduction: This study investigates the potential of an in-situ forming scaffold using a fibrin-based scaffold derived from autologous plasma combined with Synthetic Teriparatide (TP) for bone regeneration application. TP is known for its bone formation stimulation but has limited clinical use due to side effects. This autologous delivery system aims to provide precise, controlled, localized, and long-term release of TP for accelerating bone regeneration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!